Search

Displaying results 4311 - 4320 of 5898 in total
  1. Drug

    MVA-BN-brachyury-TRICOM vaccine

    go.drugbank.com/drugs/DB17424
    Investigational

    These immune-enhancing co-stimulatory molecules exert immunostimulatory and antineoplastic actions. … molecules (TRICOM), which is comprised of the three human immune-enhancing co-stimulatory molecules B7-1, ICAM-1 and LFA-3.

  2. Drug

    Subasumstat

    go.drugbank.com/drugs/DB16406
    Investigational

    Subasumstat is under investigation in clinical trial NCT03648372 (A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics (PK) of TAK-981 in Adult Participants With Advanced

  3. Drug

    Isoniazid

    go.drugbank.com/drugs/DB00951
    ApprovedInvestigational

    Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  4. Drug

    TTP889

    go.drugbank.com/drugs/DB05131
    Investigational

    TTP889 has proven to be effective in preventing clot formation in several animal models of human disease, without any signs of the bleeding associated with traditional anticoagulants.

  5. Drug

    Imidafenacin

    go.drugbank.com/drugs/DB09262
    Investigational

    It antagonizes muscarinic receptors in the bladder to reduce the frequency of urination in the treatment of overactive bladder.

  6. Drug

    Dihydroetorphine

    go.drugbank.com/drugs/DB01450
    ExperimentalIllicit

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  7. Drug

    Imipramine oxide

    go.drugbank.com/drugs/DB13782
    Experimental

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  8. Drug

    Lofepramine

    go.drugbank.com/drugs/DB13411
    Experimental

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  9. Drug

    KAND567

    go.drugbank.com/drugs/DB16511
    Investigational

    KAND567, a small molecule, blocks the fractaline (CX3CL1) receptor, which mediates the immune system response to inflammation[L32908].

  10. Drug

    Ertiprotafib

    go.drugbank.com/drugs/DB06521
    Experimental

    Ertiprotafib belongs to a novel class of insulin sensitizers developed for treatment of type 2 diabetes.